Tempus, co-founded by Eric Lefkofsky, is based in Chicago and is aiming to fight cancer by making it more efficient and personalized through cutting-edge data technology. The company recently was the recipient of $80 million by investors. This impressive amount that Tempus raised was by both existing and new investors to the company. Since 2015, the company has collected investments of $210 million including the $80 million they recently received. The company has earned the rare status of being a “unicorn” investment as it is currently valued at around $1.1 billion. This label is one that only a few startups based in Chicago have earned. With around 400 employees currently, they are expanding rapidly with around 30 more being added each month with the help of the investment.
Eric Lefkofsky is not new to investing and creating companies and is probably best known for co-founding the company Groupon. With the success he has achieved, Eric Lefkofsky is also dedicated to giving back through the Lefkofsky Foundation which he started with his wife. The Lefkofsky Foundation has helped over 50 organization since creation and has a strong focus on helping children around the world. Tempus itself is a part of the portfolio of Lightbank, a company Eric Lefkofsky also helped found. Lightbank is a venture capital firm also located in Chicago that invests in disruptive technology that has the potential to revolutionize their industry.
Tempus collects and organizes the medical data of patients in a way that will ensure patients receive the best treatment for their particular cancer and genetic makeup. The system will include DNA analysis for each patient by making it affordable which will not only help personalize cancer treatment but also help predict illnesses that the patients are genetically predisposed to. Quite possibly most impressively, it can discover patterns in treatments and patients that could help lead to cures. Eric Lefkofsky’s interest in fighting cancer does not end with Tempus. He has invested generous amounts of money through the Lefkofsky Foundation to various cancer-related charities, researchers, and treatment centers.